Scipher Medicine, under new leadership, is transitioning from a diagnostics-only focus toward leveraging its vast non-oncology transcriptomic data for precision medicine development. The firm holds one of the world’s largest clinical transcriptomic datasets for rheumatoid arthritis and is actively entering data-sharing partnerships, including a recent collaboration with Savant Bio, to enable advanced clinicogenomic insights. CEO Reg Seeto emphasized that this approach follows successful oncology models like Caris Life Sciences and Tempus, aiming to facilitate biomarker discovery and drug development in immunology and other fields beyond cancer.